Comparative Pharmacology
Head-to-head clinical analysis: ALDURAZYME versus ELAPRASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDURAZYME versus ELAPRASE.
ALDURAZYME vs ELAPRASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
Idursulfase is a recombinant form of iduronate-2-sulfatase, the enzyme deficient in Hunter syndrome (MPS II). It hydrolyzes 2-sulfate groups from the terminal iduronate sulfate glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, thereby reducing GAG accumulation in tissues.
0.58 mg/kg administered intravenously once weekly.
0.58 mg/kg IV once weekly administered over 1 hour
None Documented
None Documented
Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses
Terminal half-life: 6.5–8.5 hours (mean 7.5 h) in pediatric patients; supports weekly IV dosing
Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are reused or excreted
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy